NCT01736410已完成2 期
A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
National Cancer Centre, Singapore1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2010年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Overall Response Rate (ORR)
研究概览
简要总结
To explore overall response rate of trastuzumab combined with TS-ONE based chemotherapy in first-line HER2-positive advanced gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed adenocarcinoma of the stomach and Gastric-esophageal junction.
- •Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as more than or equals to 20 mm with conventional techniques or as more than or equals to 10 mm with spiral CT scan.
- •Patients without prior systemic treatment. Patients who completed postoperative adjuvant chemotherapy (and radiotherapy) more than 180 days before may be enrolled.
- •Age more than or equals to 21 years.
- •Life expectancy of greater than 3 months.
- •ECOG performance status less than or equals to 2 (Karnofsky more than or equals to 60%).
- •Patients must have normal organ and marrow function as defined below:
- •Hemoglobin > 8.0 g/dL
- •Leukocytes > 3,000/mcL
- •Absolute neutrophil count > 1,500/mcL
- •Platelets > 100,000/mcL
- •Total bilirubin less than or equals to 1.5 X ULN
- •AST (SGOT)/ALT (SGPT) less than or equals to 3 x institutional upper limit of normal
- •ALP less than or equals to 3 x upper limit of normal*
- •Creatinine within normal institutional limits OR Creatinine clearance** >60 mL/min for patients with creatinine levels above institutional normal
- •In the presence of liver metastasis, patients with AST, ALT and ALP < or = 5 x the upper limit of normal may be admitted. *In the presence of bone metastasis, patients with AST ,ALT and ALP < or = 10x the upper limit of normal maybe admitted. **: Creatinine clearance can be estimated using Cockcroft-Gault formula man: Ccr (mL/min) = body weight (kg) x (140 - age)/(72 x serum creatinine (mg/dL)), woman: Ccr = male Ccr x 0.85]. The above CrCl Formula is to be applied in all sites.
- •Patients who have HER2-positive cancer confirmed with IHC and/or FISH***.
- •*** Immunohistochemistry (IHC) for HER-2 is routine as part of pathological evaluation of gastric hybridisation (FISH) for Her2 copy number is required. A copy number value above 2.2 is taken as positive. The sponsors for the drugs used in our investigator initiated trial (Taiho) have kindly agreed to pay for the HER2 FISH test.
- •Patients able to take orally.
- •Patients with left ventricular ejection fraction of at least 50% on MUGA or 2D-echocardiography done within 28 days before enrollment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- •The effects of proposed regimen on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because antitumor agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
- •Ability to understand and the willingness to sign a written informed consent document.
- •Consent for fresh frozen tissue collection, mandatory for patients with primary in-situ tumors and optional for patients without primary in-situ tumors.
- •Tissue collection only applicable to National Cancer Centre (S) and National University Hospital (S)
排除标准
- •Patients who have had radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to treatment administered more than 4 weeks earlier.
- •Patients receiving any other investigational agents.
- •Patients with known brain metastases.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to TS-ONE, cisplatin and trastuzumab or other agents used in the study.
- •Presence of any contraindications to TS-ONE or cisplatin or trastuzumab.
- •Baseline LVEF (Left Ventricular Ejection Fraction) < 50%.
- •Patients with serious (e.g.inpatient care is needed) complications (e.g. intestinal paralysis, intestinal occlusion, interstitial pneumonia or pulmonary fibrosis, poorly-controlled diabetes, renal failure or hepatic cirrhosis).
- •Patients with massive ascites (moderate or higher, beyond the pelvic cavity and retention on the anterior surface of the liver on CT) or massive pleural effusion retention.
- •Patients with fresh bleeding from the digestive tract which needs repeated blood transfusion.
- •Patients with diarrhea (4 or more times per day or watery diarrhea).
- •Previous malignancy other than gastric cancer diagnosed in the last 5 years except for basal cell carcinoma of skin or preinvasive cancer of cervix.
- •Patients with reproductive potential who refuse to use an adequate means of contraception (including male patients).
- •Significant disease or conditions which, in the investigator's opinion, would exclude patient from the study.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant or lactating female.
- •HIV-positive patients.
研究组 & 干预措施
IHC method
Other
干预措施: Trastuzumab, TS ONE, Cisplatin (Drug)
FISH method
Other
干预措施: Trastuzumab, TS ONE, Cisplatin (Drug)
结局指标
主要结局
Overall Response Rate (ORR)
时间窗: 24 months
次要结局
- Progression free survival (PFS)(24 months)
- Overall survival (OS)(24 months)
- Time to Treatment Failure (TTF)(24 months)
研究者
Choo Su Pin
Doctor
National Cancer Centre, Singapore
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive SystemTargeted TherapyHER2Biliary Tract CancerEsophageal Squamous Cell CarcinomaColorectal CancerNCT03185988Shen Lin100
Unknown
2 期
A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerGastric CancerNCT01228045National University Hospital, Singapore30
招募中
2 期
Phase II single-arm study of Trastuzumab combination with Cisplatin and Gemcitabine as first-line therapy in the HER-2 positive Advanced CholangioCArcinomaAdvanced biliary tract cancersHER-2 positiveFirst-line therapyGallbladder CancerBiliary Tract CancersOncogene Protein HER-2TrastuzumabCisplatinGemcitabineCancer Chemotherapy AgentCombined Antineoplastic AgentsCholangiocarcinomaTCTR20220328005Khon Kaen University33
已完成
2 期
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2Colorectal CancerNCT00003995National Cancer Institute (NCI)32
已完成
1 期
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)Advanced Breast CancerNCT01976169University of Texas Southwestern Medical Center29